Trial Profile
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ORARIALS-01
- Sponsors Orphazyme; Zevra Therapeutics
- 07 May 2021 Results published in the Orphazyme media release.
- 07 May 2021 Results presented in a CytRx Corporation Media Release.
- 07 May 2021 According to Orphazyme media release, the topline data will be presented at the upcoming virtual European Network to Cure ALS (ENCALS) meeting, May 12-14, and complete data from the study will be published later this year.